Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Photoacoustic imaging and artificial intelligence-based theranostic approach for cancer

Project description

A new era in micro-level disease combat

In the intricate realm of healthcare, the challenge of combatting chemoresistant neoplastic lesions under 1 mm in size has persistently confounded medical experts. By evading conventional diagnostic and therapeutic methods, these lesions pose a serious threat to patient well-being. In this context, the EIC-funded PHIRE project aims to reshape this landscape, offering a beacon of hope in the form of a revolutionary high-resolution theranostic medical device that integrates an add-on module for deep organ imaging, guided by AI-driven gold nanorod therapy. Crucially, urine-stable nanorods ensure safety. Overall, PHIRE’s potential to reduce relapses and patient burden marks a paradigm shift. Beyond medicine, PHIRE resonates in imaging, nanotechnology and software markets.

Objective

"Health programs crave for diagnostic imaging and eradication of chemoresistant neoplastic lesions smaller than 1 mm of size. PHIRE, based on the outcomes from EDIT (FET-OPEN-RIA, GA#801126), aims at bringing closer to market a novel high-resolution theranostic medical device effective in the clinical applications for lesions <1 mm, ready for application in human bladder cancer and effective both in male and female patients.

The PHIRE solution will be developed using swine model and will include:
- an add-on module for pre-existing off-the shelf photoacoustic device allowing to perform photoacoustic imaging of hollow organs located deeper in human body, designed to be used in combination with
- an artificial intelligence-assisted prediction map for the image-guided gold nanorods assisted photo-thermal therapy,
- a large-scale synthesis of urine-stable gold nanorods for clinical use.

The adoption for clinical applications of this new device will reduce the frequency of the bladder tumor relapse and the number of patients with relapsing tumor, with a drastic positive impact on the quality of life of patients while reducing the social cost of the management of patients. Furthermore, PHIRE’s results will open up the way for the deployment of theranostic application against lesions <1 mm in other hollow human organs.

PHIRE innovative solutions will also be applicable to other markets, such as that of photoacoustic and diagnostic imaging, gold nanoparticles, cystoscopy and medical software.

"

Coordinator

OSPEDALE SAN RAFFAELE SRL
Net EU contribution
€ 701 250,00
Address
VIA OLGETTINA 60
20132 Milano
Italy

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 701 250,00

Participants (3)

Partners (1)